4EASL International consensus conference on hepatitis B.Consensus state[J].J Hepatology,2003,39(suppl):s3-s25.
5Lok ASF,McMahon B J.AASLD Practice guideline.Chronic Hepatitis B:Update of Recommendations[J].Hepatology,2004,39(3):857-861.
6Liaw,YF,Leung N,Guan R,et al.Aisan-Pacific consensus statement on the management of chronic hepatitis B:a 2005 update.Liver Intemal[J].2005,25:472-489.
7Lewin SR,Ribeiro RM,Walters T,et al.Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed[J].Hepatology,2002,34(5):1012-1020.
8Lok AS,Lai CL,Leung N,et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Castroenterology,2003,125(6):1714-1722.
9Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,351(15):1521-1531.
10Orito E,Fujiwam K,Tanaka Y,et al.A case-control Study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B vires of genotypes Sj,Ba and C[J].Hepatol Res,2006,35(2):127-134.
